Prospective Prenatal Cell-Free DNA Screening for Genetic Conditions of Heterogenous Etiologies
Jinglan Zhang,Yanting Wu,Songchang Chen,Qiong Luo,Hui Xi,Jianli Li,Xiaomei Qin,Ying Peng,Na Ma,Bingxin Yang,Xiang Qiu,Weiliang Lu,Yuan Chen,Ying Jiang,Panpan Chen,Yifeng Liu,Chen Zhang,Zhiwei Zhang,Yu Xiong,Jie Shen,Huan Liang,Yunyun Ren,Chunmei Ying,Minyue Dong,Xiaotian Li,Congjian Xu,Hua Wang,Dan Zhang,Chenming Xu,Hefeng Huang
DOI: https://doi.org/10.1038/s41591-023-02774-x
IF: 82.9
2024-01-01
Nature Medicine
Abstract:Prenatal cell-free DNA (cfDNA) screening uses extracellular fetal DNA circulating in the peripheral blood of pregnant women to detect prevalent fetal chromosomal anomalies. However, numerous severe conditions with underlying single-gene defects are not included in current prenatal cfDNA screening. In this prospective, multicenter and observational study, pregnant women at elevated risk for fetal genetic conditions were enrolled for a cfDNA screening test based on coordinative allele-aware target enrichment sequencing. This test encompasses the following three of the most frequent pathogenic genetic variations: aneuploidies, microdeletions and monogenic variants. The cfDNA screening results were compared to invasive prenatal or postnatal diagnostic test results for 1,090 qualified participants. The comprehensive cfDNA screening detected a genetic alteration in 135 pregnancies with 98.5% sensitivity and 99.3% specificity relative to standard diagnostics. Of 876 fetuses with suspected structural anomalies on ultrasound examination, comprehensive cfDNA screening identified 55 (56.1%) aneuploidies, 6 (6.1%) microdeletions and 37 (37.8%) single-gene pathogenic variants. The inclusion of targeted monogenic conditions alongside chromosomal aberrations led to a 60.7% increase (from 61 to 98) in the detection rate. Overall, these data provide preliminary evidence that a comprehensive cfDNA screening test can accurately identify fetal pathogenic variants at both the chromosome and single-gene levels in high-risk pregnancies through a noninvasive approach, which has the potential to improve prenatal evaluation of fetal risks for severe genetic conditions arising from heterogenous molecular etiologies. ClinicalTrials.gov registration: ChiCTR2100045739 .